Related Experiment Video
Updated: Feb 6, 2026
11:20
Site-Directed Immobilization of Bone Morphogenetic Protein 2 to Solid Surfaces by Click Chemistry
Published on: March 29, 2018
8.0K
The Osteoinductive Effect of Controlled Bone Morphogenic Protein 2 Release Is Location Dependent
Maurits G L Olthof1,2,3,4,5, Lichun Lu2,3, Marianna A Tryfonidou4
11 Department of Orthopaedics, University Medical Center, Utrecht, The Netherlands.
Tissue Engineering. Part A
|August 14, 2018
Summary
This study developed a novel hydrogel to extend the activity of bone morphogenic protein 2 (BMP-2) for bone tissue engineering. The new material shows superior performance compared to existing clinical treatments, highlighting the importance of scaffold design.
Area of Science:
- Biomaterials Science
- Regenerative Medicine
- Orthopedic Research
Background:
- Bone morphogenic protein 2 (BMP-2) has a short biological half-life, limiting its efficacy in bone tissue engineering.
- Current clinical applications face challenges in prolonging BMP-2's biologic activity.
- Developing advanced biomaterials is crucial for effective bone regeneration strategies.
Purpose of the Study:
- To develop and evaluate a phosphate-modified oligo[(polyethylene glycol) fumarate] hydrogel for sustained BMP-2 release.
- To compare the efficacy of this novel hydrogel platform against a clinically used product (Infuse®).
- To investigate the influence of implantation location on the osteoinductive effect of BMP-2.
Main Methods:
- Fabrication of a tunable phosphate-modified oligo[(polyethylene glycol) fumarate] hydrogel.
- Assessment of differential release profiles for biologically active BMP-2.
- In vivo evaluation of the hydrogel's osteoinductive capacity at orthotopic and subcutaneous locations.
- Comparative analysis with Infuse® for bone tissue engineering efficacy.
Main Results:
- The novel hydrogel platform demonstrated tunable BMP-2 release profiles.
- The developed hydrogel outperformed Infuse® in promoting bone regeneration.
- The osteoinductive effect of BMP-2 was found to be location-dependent, with superior results at the orthotopic site.
- Biomaterial scaffolds play a critical role in achieving successful bone tissue engineering.
Conclusions:
- Phosphate-modified oligo[(polyethylene glycol) fumarate] hydrogels offer a promising platform for controlled BMP-2 delivery.
- This novel biomaterial strategy surpasses current clinical standards for BMP-2 delivery in bone regeneration.
- Evaluating bone tissue engineering strategies at orthotopic sites is essential for accurate efficacy assessment.
- The design of biomaterial scaffolds is paramount for optimizing bone tissue engineering outcomes.
Related Concept Videos
01:25cAMP-dependent Protein Kinase Pathways
8.5K
Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
8.5K
01:13Location and Orientation of the Heart
10.4K
The human heart, despite its modest size and weight, is an organ of remarkable strength and endurance. Roughly the size of a fist, the heart weighs between 250 and 350 grams and is nestled within the mediastinum, the medial cavity of the thorax. It extends obliquely for about 12 to 14 cm, resting on the superior surface of the diaphragm. The heart is positioned anterior to the vertebral column and posterior to the sternum, with two-thirds of its mass lying to the left of the midsternal line.
10.4K
02:33Combinatorial Gene Control
9.7K
Combinatorial gene control is the synergistic action of several transcriptional factors to regulate the expression of a single gene. The absence of one or more of these factors may lead to a significant difference in the level of gene expression or repression.
The expression of more than 30,000 genes is controlled by approximately 2000-3000 transcription factors. This is possible because a single transcription factor can recognize more than one regulatory sequence. The specificity in gene...
The expression of more than 30,000 genes is controlled by approximately 2000-3000 transcription factors. This is possible because a single transcription factor can recognize more than one regulatory sequence. The specificity in gene...
9.7K
01:28Energy-releasing Steps of Glycolysis
146.9K
Glycolysis is divided into two phases based on whether energy is utilized or released. While the first phase consumes ATP, the second phase produces energy in the form of ATP and NADH. The energy is released over a sequence of reactions that turns G3P into pyruvate. The energy-releasing phase—steps 6-10 of glycolysis—occurs twice, once for each of the two 3-carbon sugars produced during steps 1-5 of the first phase.
The first energy-releasing step—the 6th step of glycolysis...
The first energy-releasing step—the 6th step of glycolysis...
146.9K
01:19Contact-dependent Signaling
47.6K
Contact-dependent signaling, as the name suggests, requires that communicating cells be in direct contact with each other. This is achieved either through receptor-ligand interactions or by specialized cytoplasmic channels that allow the flow of small molecules between cells. In animal cells, channels called gap junctions facilitate contact-dependent signaling in certain tissues, whereas, plasmodesmata perform a similar function in plants.
Gap Junctions
In animal cells, gap junctions are formed...
Gap Junctions
In animal cells, gap junctions are formed...
47.6K
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
912
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
912